drugset
drugset / Trial / NCT01099631

IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread

NCT01099631 ↗

Phase 1 Completed 22 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSequentialOpen-labelTreatment

Summary

The working hypothesis is that oral administration of an attenuated strain of Salmonella typhimurium is safe and efficacious for patients with unresectable hepatic metastasis from a solid tumor cancer. The primary objective of the study is to determine the MTD of Salmonella typhimurium in the treatment.

Timeline

Start
2010-04
Primary completion
2014-01
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Typhoid Vaccine Vaccine 100000 unknown Oral
Subject Typhoid Vaccine Vaccine 1e+06 unknown Oral
Subject Typhoid Vaccine Vaccine 1e+07 unknown Oral
Subject Typhoid Vaccine Vaccine 1e+08 unknown Oral
Subject Typhoid Vaccine Vaccine 1e+09 unknown Oral
Subject Typhoid Vaccine Vaccine 1e+10 unknown Oral

Indications

biliary tract cancer hepatocellular carcinoma